IDO1 and cancer: Therefore, IDO inhibitors in combination with ICI-based immunotherapies or standard treatments deserve thorough investigations in cancer, and more clinical studies with immune monitoring are required to evaluate the impact of IDO-1-targeting on modulating the immunological landscape of TME.